Literature DB >> 16081156

No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.

Marianna Politou, Anastasios Karadimitris, Evangelos Terpos, Ioannis Kotsianidis, Jane F Apperley, Amin Rahemtulla.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16081156     DOI： 10.1016/j.leukres.2005.06.014

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  29 in total

1.  Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.

Authors:  Chungyee Leung-Hagesteijn; Natalie Erdmann; Grace Cheung; Jonathan J Keats; A Keith Stewart; Donna E Reece; Kim Chan Chung; Rodger E Tiedemann
Journal:  Cancer Cell       Date:  2013-09-09       Impact factor: 31.743

2.  CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma.

Authors:  Chang-Xin Shi; K Martin Kortüm; Yuan Xiao Zhu; Laura A Bruins; Patrick Jedlowski; Patrick G Votruba; Moulun Luo; Robert A Stewart; Jonathan Ahmann; Esteban Braggio; A Keith Stewart
Journal:  Mol Cancer Ther       Date:  2017-09-27       Impact factor: 6.261

3.  Molecular mechanisms of acquired proteasome inhibitor resistance.

Authors:  Andrew J Kale; Bradley S Moore
Journal:  J Med Chem       Date:  2012-10-03       Impact factor: 7.446

4.  Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.

Authors:  Li Yin; Turner Kufe; David Avigan; Donald Kufe
Journal:  Blood       Date:  2014-03-14       Impact factor: 22.113

5.  The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma.

Authors:  Bingzong Li; Jinxiang Fu; Ping Chen; Xueping Ge; Yali Li; Isere Kuiatse; Hua Wang; Huihan Wang; Xingding Zhang; Robert Z Orlowski
Journal:  J Biol Chem       Date:  2015-10-19       Impact factor: 5.157

6.  Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.

Authors:  Deborah J Kuhn; Zuzana Berkova; Richard J Jones; Richard Woessner; Chad C Bjorklund; Wencai Ma; R Eric Davis; Pei Lin; Hua Wang; Timothy L Madden; Caimiao Wei; Veerabhadran Baladandayuthapani; Michael Wang; Sheeba K Thomas; Jatin J Shah; Donna M Weber; Robert Z Orlowski
Journal:  Blood       Date:  2012-08-29       Impact factor: 22.113

7.  Single-molecule analysis reveals widespread structural variation in multiple myeloma.

Authors:  Aditya Gupta; Michael Place; Steven Goldstein; Deepayan Sarkar; Shiguo Zhou; Konstantinos Potamousis; Jaehyup Kim; Claire Flanagan; Yang Li; Michael A Newton; Natalie S Callander; Peiman Hematti; Emery H Bresnick; Jian Ma; Fotis Asimakopoulos; David C Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-08       Impact factor: 11.205

8.  The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.

Authors:  Marianne Kraus; Juergen Bader; Paul P Geurink; Emily S Weyburne; Anne C Mirabella; Tobias Silzle; Tamer B Shabaneh; Wouter A van der Linden; Gerjan de Bruin; Sarah R Haile; Eva van Rooden; Christina Appenzeller; Nan Li; Alexei F Kisselev; Herman Overkleeft; Christoph Driessen
Journal:  Haematologica       Date:  2015-06-11       Impact factor: 9.941

9.  Dominant-negative NFKBIA mutation promotes IL-1β production causing hepatic disease with severe immunodeficiency.

Authors:  Enrica Ek Tan; Richard A Hopkins; Chrissie K Lim; Saumya S Jamuar; Christina Ong; Koh C Thoon; Mark Ja Koh; Eun Mong Shin; Derrick Wq Lian; Madhushanee Weerasooriya; Christopher Zw Lee; Andreas Alvin Pumomo Soetedjo; Chang Siang Lim; Veonice B Au; Edmond Chua; Hui Yin Lee; Leigh Ann Jones; Sharmy S James; Nivashini Kaliaperumal; Jeffery Kwok; Ee Shien Tan; Biju Thomas; Lynn Xue Wu; Lena Ho; Anna Marie Fairhurst; Florent Ginhoux; Adrian Kk Teo; Yong Liang Zhang; Kok Huar Ong; Weimiao Yu; Byrappa Venkatesh; Vinay Tergaonkar; Bruno Reversade; Keh Chuang Chin; Ah Moy Tan; Woei Kang Liew; John E Connolly
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

Review 10.  Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.

Authors:  Jacob P Laubach; Constantine S Mitsiades; Aldo M Roccaro; Irene M Ghobrial; Kenneth C Anderson; Paul G Richardson
Journal:  Leuk Lymphoma       Date:  2009-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.